Portuguese recommendations for the use of methotrexate in rheumatic diseases - 2016 update

Ana Catarina Duarte; Daniela Santos-Faria; Maria João Gonçalves; Alexandre Sepriano; Ana Filipa Mourão; Cátia Duarte; Joana Sousa Neves; Ana Filipa Águeda; Pedro Avila Ribeiro; Alexandra Daniel; Adriano Neto; Ana Cordeiro; Ana Rodrigues; Anabela Barcelos; Cândida Silva; Cristina Ponte; Elsa Vieira-Sousa; Filipa Teixeira; Filipa Oliveira-Ramos; Filipe Araújo; Filipe Barcelos; Helena Canhão; Helena Santos; João Ramos; Joaquim Polido-Pereira; José Tavares-Costa; José António Melo Gomes; Luís Cunha-Miranda; Lúcia Costa; Marcos Cerqueira; Margarida Cruz; Maria José Santos; Miguel Bernardes; Paula Oliveira; Pedro Abreu; Ricardo Figueira; Rita Barros; Sandra Falcão; Patrícia Pinto; Sofia Pimenta; Susana Capela; Vitor Teixeira; João Eurico Fonseca

Portuguese recommendations for the use of methotrexate in rheumatic diseases - 2016 update

Ana Catarina Duarte, Daniela Santos-Faria, Maria João Gonçalves, Alexandre Sepriano, Ana Filipa Mourão, Cátia Duarte, Joana Sousa Neves, Ana Filipa Águeda, Pedro Avila Ribeiro, Alexandra Daniel, Adriano Neto, Ana Cordeiro, Ana Rodrigues, Anabela Barcelos, Cândida Silva, Cristina Ponte, Elsa Vieira-Sousa, Filipa Teixeira, Filipa Oliveira-Ramos, Filipe AraújoFilipe Barcelos, Helena Canhão, Helena Santos, João Ramos, Joaquim Polido-Pereira, José Tavares-Costa, José António Melo Gomes, Luís Cunha-Miranda, Lúcia Costa, Marcos Cerqueira, Margarida Cruz, Maria José Santos, Miguel Bernardes, Paula Oliveira, Pedro Abreu, Ricardo Figueira, Rita Barros, Sandra Falcão, Patrícia Pinto, Sofia Pimenta, Susana Capela, Vitor Teixeira, João Eurico Fonseca

Research output: Contribution to journal › Article › peer-review

9 Citations (Scopus)

18 Downloads (Pure)

Abstract

BACKGROUND: Methotrexate (MTX) is the first-line drug in the treatment of rheumatoid arthritis (RA) and the most commonly prescribed disease modifying anti-rheumatic drug. Moreover, it is also used as an adjuvant drug in patients under biologic therapies, enhancing the efficacy of biologic agents.

OBJECTIVES: To review the literature and update the Portuguese recommendations for the use of MTX in rheumatic diseases first published in 2009.

METHODS: The first Portuguese guidelines for the use of MTX in rheumatic diseases were published in 2009 and were integrated in the multinational 3E Initiative (Evidence Expertise Exchange) project. The Portuguese rheumatologists based on literature evidence and consensus opinion formulated 13 recommendations. At a national meeting, the recommendations included in this document were further discussed and updated. The document resulting from this meeting circulated to all Portuguese rheumatologists, who anonymously voted online on the level of agreement with the updated recommendations.

RESULTS: Results presented in this article are mainly in accordance with previous guidelines, with some new information regarding hepatitis B infection during MTX treatment, pulmonary toxicity monitoring, hepatotoxicity management, association with hematologic neoplasms, combination therapy and tuberculosis screening during treatment.

CONCLUSION: The present recommendations combine scientific evidence with expert opinion and attained desirable agreement among Portuguese rheumatologists. The regular update of these recommendations is essential in order to keep them a valid and useful tool in daily practice.

Original language	English
Pages (from-to)	127-140
Number of pages	14
Journal	Acta Reumatológica Portuguesa
Volume	42
Issue number	2
Publication status	Published - 24 May 2017

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

1175_portuguese_recommendations_for_the_use_of_methotrexate_in_rheumatic_diseases_2016_update_fileFinal published version, 300 KBLicence: CC BY-NC-ND

http://www.actareumatologica.pt/archive_detail.php?id=214Licence: CC BY-NC-ND

Cite this

Duarte, A. C., Santos-Faria, D., Gonçalves, M. J., Sepriano, A., Mourão, A. F., Duarte, C., Neves, J. S., Águeda, A. F., Ribeiro, P. A., Daniel, A., Neto, A., Cordeiro, A., Rodrigues, A., Barcelos, A., Silva, C., Ponte, C., Vieira-Sousa, E., Teixeira, F., Oliveira-Ramos, F., ... Fonseca, J. E. (2017). Portuguese recommendations for the use of methotrexate in rheumatic diseases - 2016 update. Acta Reumatológica Portuguesa, 42(2), 127-140. http://www.actareumatologica.pt/archive_detail.php?id=214

@article{72df6aac4f4847a79c72343b95e0f062,

title = "Portuguese recommendations for the use of methotrexate in rheumatic diseases - 2016 update",

abstract = "BACKGROUND: Methotrexate (MTX) is the first-line drug in the treatment of rheumatoid arthritis (RA) and the most commonly prescribed disease modifying anti-rheumatic drug. Moreover, it is also used as an adjuvant drug in patients under biologic therapies, enhancing the efficacy of biologic agents.OBJECTIVES: To review the literature and update the Portuguese recommendations for the use of MTX in rheumatic diseases first published in 2009.METHODS: The first Portuguese guidelines for the use of MTX in rheumatic diseases were published in 2009 and were integrated in the multinational 3E Initiative (Evidence Expertise Exchange) project. The Portuguese rheumatologists based on literature evidence and consensus opinion formulated 13 recommendations. At a national meeting, the recommendations included in this document were further discussed and updated. The document resulting from this meeting circulated to all Portuguese rheumatologists, who anonymously voted online on the level of agreement with the updated recommendations.RESULTS: Results presented in this article are mainly in accordance with previous guidelines, with some new information regarding hepatitis B infection during MTX treatment, pulmonary toxicity monitoring, hepatotoxicity management, association with hematologic neoplasms, combination therapy and tuberculosis screening during treatment.CONCLUSION: The present recommendations combine scientific evidence with expert opinion and attained desirable agreement among Portuguese rheumatologists. The regular update of these recommendations is essential in order to keep them a valid and useful tool in daily practice.",

author = "Duarte, {Ana Catarina} and Daniela Santos-Faria and Gon{\c c}alves, {Maria Jo{\~a}o} and Alexandre Sepriano and Mour{\~a}o, {Ana Filipa} and C{\'a}tia Duarte and Neves, {Joana Sousa} and {\'A}gueda, {Ana Filipa} and Ribeiro, {Pedro Avila} and Alexandra Daniel and Adriano Neto and Ana Cordeiro and Ana Rodrigues and Anabela Barcelos and C{\^a}ndida Silva and Cristina Ponte and Elsa Vieira-Sousa and Filipa Teixeira and Filipa Oliveira-Ramos and Filipe Ara{\'u}jo and Filipe Barcelos and Helena Canh{\~a}o and Helena Santos and Jo{\~a}o Ramos and Joaquim Polido-Pereira and Jos{\'e} Tavares-Costa and {Melo Gomes}, {Jos{\'e} Ant{\'o}nio} and Lu{\'i}s Cunha-Miranda and L{\'u}cia Costa and Marcos Cerqueira and Margarida Cruz and Santos, {Maria Jos{\'e}} and Miguel Bernardes and Paula Oliveira and Pedro Abreu and Ricardo Figueira and Rita Barros and Sandra Falc{\~a}o and Patr{\'i}cia Pinto and Sofia Pimenta and Susana Capela and Vitor Teixeira and Fonseca, {Jo{\~a}o Eurico}",

year = "2017",

month = may,

day = "24",

language = "English",

volume = "42",

pages = "127--140",

journal = "Acta Reumatol{\'o}gica Portuguesa",

issn = "0303-464X",

publisher = "Sociedade Portuguesa de Reumatologia",

number = "2",

}

Duarte, AC, Santos-Faria, D, Gonçalves, MJ, Sepriano, A , Mourão, AF, Duarte, C, Neves, JS, Águeda, AF, Ribeiro, PA, Daniel, A, Neto, A, Cordeiro, A , Rodrigues, A, Barcelos, A, Silva, C, Ponte, C, Vieira-Sousa, E, Teixeira, F, Oliveira-Ramos, F, Araújo, F, Barcelos, F, Canhão, H , Santos, H, Ramos, J, Polido-Pereira, J, Tavares-Costa, J, Melo Gomes, JA, Cunha-Miranda, L, Costa, L, Cerqueira, M, Cruz, M, Santos, MJ, Bernardes, M, Oliveira, P, Abreu, P, Figueira, R, Barros, R, Falcão, S, Pinto, P, Pimenta, S, Capela, S, Teixeira, V & Fonseca, JE 2017, 'Portuguese recommendations for the use of methotrexate in rheumatic diseases - 2016 update', Acta Reumatológica Portuguesa, vol. 42, no. 2, pp. 127-140. <http://www.actareumatologica.pt/archive_detail.php?id=214>

TY - JOUR

T1 - Portuguese recommendations for the use of methotrexate in rheumatic diseases - 2016 update

AU - Duarte, Ana Catarina

AU - Santos-Faria, Daniela

AU - Gonçalves, Maria João

AU - Sepriano, Alexandre

AU - Mourão, Ana Filipa

AU - Duarte, Cátia

AU - Neves, Joana Sousa

AU - Águeda, Ana Filipa

AU - Ribeiro, Pedro Avila

AU - Daniel, Alexandra

AU - Neto, Adriano

AU - Cordeiro, Ana

AU - Rodrigues, Ana

AU - Barcelos, Anabela

AU - Silva, Cândida

AU - Ponte, Cristina

AU - Vieira-Sousa, Elsa

AU - Teixeira, Filipa

AU - Oliveira-Ramos, Filipa

AU - Araújo, Filipe

AU - Barcelos, Filipe

AU - Canhão, Helena

AU - Santos, Helena

AU - Ramos, João

AU - Polido-Pereira, Joaquim

AU - Tavares-Costa, José

AU - Melo Gomes, José António

AU - Cunha-Miranda, Luís

AU - Costa, Lúcia

AU - Cerqueira, Marcos

AU - Cruz, Margarida

AU - Santos, Maria José

AU - Bernardes, Miguel

AU - Oliveira, Paula

AU - Abreu, Pedro

AU - Figueira, Ricardo

AU - Barros, Rita

AU - Falcão, Sandra

AU - Pinto, Patrícia

AU - Pimenta, Sofia

AU - Capela, Susana

AU - Teixeira, Vitor

AU - Fonseca, João Eurico

PY - 2017/5/24

Y1 - 2017/5/24

N2 - BACKGROUND: Methotrexate (MTX) is the first-line drug in the treatment of rheumatoid arthritis (RA) and the most commonly prescribed disease modifying anti-rheumatic drug. Moreover, it is also used as an adjuvant drug in patients under biologic therapies, enhancing the efficacy of biologic agents.OBJECTIVES: To review the literature and update the Portuguese recommendations for the use of MTX in rheumatic diseases first published in 2009.METHODS: The first Portuguese guidelines for the use of MTX in rheumatic diseases were published in 2009 and were integrated in the multinational 3E Initiative (Evidence Expertise Exchange) project. The Portuguese rheumatologists based on literature evidence and consensus opinion formulated 13 recommendations. At a national meeting, the recommendations included in this document were further discussed and updated. The document resulting from this meeting circulated to all Portuguese rheumatologists, who anonymously voted online on the level of agreement with the updated recommendations.RESULTS: Results presented in this article are mainly in accordance with previous guidelines, with some new information regarding hepatitis B infection during MTX treatment, pulmonary toxicity monitoring, hepatotoxicity management, association with hematologic neoplasms, combination therapy and tuberculosis screening during treatment.CONCLUSION: The present recommendations combine scientific evidence with expert opinion and attained desirable agreement among Portuguese rheumatologists. The regular update of these recommendations is essential in order to keep them a valid and useful tool in daily practice.

AB - BACKGROUND: Methotrexate (MTX) is the first-line drug in the treatment of rheumatoid arthritis (RA) and the most commonly prescribed disease modifying anti-rheumatic drug. Moreover, it is also used as an adjuvant drug in patients under biologic therapies, enhancing the efficacy of biologic agents.OBJECTIVES: To review the literature and update the Portuguese recommendations for the use of MTX in rheumatic diseases first published in 2009.METHODS: The first Portuguese guidelines for the use of MTX in rheumatic diseases were published in 2009 and were integrated in the multinational 3E Initiative (Evidence Expertise Exchange) project. The Portuguese rheumatologists based on literature evidence and consensus opinion formulated 13 recommendations. At a national meeting, the recommendations included in this document were further discussed and updated. The document resulting from this meeting circulated to all Portuguese rheumatologists, who anonymously voted online on the level of agreement with the updated recommendations.RESULTS: Results presented in this article are mainly in accordance with previous guidelines, with some new information regarding hepatitis B infection during MTX treatment, pulmonary toxicity monitoring, hepatotoxicity management, association with hematologic neoplasms, combination therapy and tuberculosis screening during treatment.CONCLUSION: The present recommendations combine scientific evidence with expert opinion and attained desirable agreement among Portuguese rheumatologists. The regular update of these recommendations is essential in order to keep them a valid and useful tool in daily practice.

M3 - Article

C2 - 28535545

SN - 0303-464X

VL - 42

SP - 127

EP - 140

JO - Acta Reumatológica Portuguesa

JF - Acta Reumatológica Portuguesa

IS - 2

ER -

Portuguese recommendations for the use of methotrexate in rheumatic diseases - 2016 update

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this